- Stocks
- Pharma & Healthcare
- Fredun Pharmace
Fredun Pharmace share price
NSE: FREDUNPharma & HealthcareDrug Manufacturers - Specialty & Generic
Fredun Pharmace at a glance
Fredun Pharmace (NSE: FREDUN) closed at ₹1,435.00 on 19 Oct 2026, down 3.04% on the day. With a market capitalisation of ₹2,373 Cr, it ranks 1089th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 23.4× trailing earnings, against a return on equity of 14.7% in FY25. Its 52-week range is ₹1,195.20 (16 Sep 2026) to ₹1,665.00 (8 Oct 2026); the last close is 13.8% below the high. Promoters held 44.57% of the company as of 16 Jul 2026.
Key numbers
- Market cap
- ₹2,373 CrRank 1089 on NSE
- P/E (trailing)
- 23.4×
- Price to book
- 2.23×FY25
- ROE
- 14.7%FY25
- ROCE
- 31.8%FY25
- Debt to equity
- 1.18FY25
- Net profit margin
- 4.6%FY25
- Book value / share
- ₹299.47FY25
- Dividend payout
- 1.6%FY25
- 52-week high
- ₹1,665.008 Oct 2026
- 52-week low
- ₹1,195.2016 Sep 2026
- RSI (14-day)
- 49.1
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −3.04% | −5.5% | +12.1% | — | — |
Fredun Pharmace financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹113 Cr | ₹134 Cr | ₹224 Cr | ₹275 Cr | ₹348 Cr | ₹454 Cr |
| Operating profit | ₹2 Cr | ₹4 Cr | ₹9 Cr | ₹18 Cr | ₹21 Cr | ₹28 Cr |
| Net profit | ₹2 Cr | ₹2 Cr | ₹6 Cr | ₹11 Cr | ₹16 Cr | ₹21 Cr |
| EPS (₹) | ₹4.77 | ₹5.05 | ₹11.28 | ₹24.13 | ₹33.66 | ₹44.83 |
| Cash from operations | −₹11 Cr | ₹0 Cr | −₹2 Cr | −₹14 Cr | −₹0 Cr | −₹29 Cr |
| Total debt | ₹12 Cr | ₹29 Cr | ₹42 Cr | ₹49 Cr | ₹13 Cr | ₹10 Cr |
| Shareholders' equity | ₹41 Cr | ₹43 Cr | ₹68 Cr | ₹96 Cr | ₹121 Cr | ₹141 Cr |
Fredun Pharmace shareholding pattern
| Holder | 20 Feb 2026 | 25 Mar 2026 | 31 Mar 2026 | 9 Apr 2026 | 30 Jun 2026 | 16 Jul 2026 |
|---|---|---|---|---|---|---|
| Promoters | 43.06% | 44.17% | 44.17% | 44.57% | 44.57% | 44.57% |
| Foreign institutions | 1.06% | 1.06% | 1.06% | 1.06% | 1.06% | 1.06% |
| Domestic institutions | 2.89% | 2.83% | 2.83% | 2.81% | 2.94% | 2.94% |
| Non-institutions | 52.99% | 51.94% | 51.94% | 51.56% | 51.43% | 51.43% |
Fredun Pharmace vs peers
The listed Pharma & Healthcare companies nearest to Fredun Pharmace by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| DRAGARWQDr Agarwals Eye Hospital | ₹5,083.50 | +0.46% | — | ₹2,457 Cr | — | — |
| ALEMBICLTDAlembic | ₹95.20 | −2.46% | −2.8% | ₹2,445 Cr | 7.7 | — |
| VENUSREMVenus Remedies | ₹1,796.10 | +5.00% | +293.9% | ₹2,401 Cr | 23.3 | — |
| FREDUNFredun Pharmace | ₹1,435.00 | −3.04% | — | ₹2,373 Cr | 23.4 | — |
| DCALDishman Carbogen Amcis | ₹146.03 | −2.65% | −50.3% | ₹2,290 Cr | 23.5 | — |
| VIMTALABSVimta Labs | ₹505.00 | −3.55% | −29.2% | ₹2,256 Cr | 29 | — |
| MEDIASSISTMedi Assist Healthcare Services | ₹297.65 | −2.89% | −43.8% | ₹2,224 Cr | 24.5 | — |
Ask anything about Fredun Pharmace
Pivot answers on the live chart with evidence you can check, and tests strategies against FREDUN's own history. Try: “Why has FREDUN moved over the last three months?” · “Backtest a 50-day moving-average crossover on FREDUN over five years” · “Compare FREDUN with DRAGARWQ on margins and valuation”
Frequently asked questions about Fredun Pharmace
What is the share price of Fredun Pharmace today?
Fredun Pharmace (NSE: FREDUN) last closed at ₹1,435.00 on 19 Oct 2026. Its 52-week high is ₹1,665.00 and its 52-week low is ₹1,195.20.
What is the market cap of Fredun Pharmace?
Fredun Pharmace's market capitalisation is ₹2,373 Cr (₹2,373 Cr) at the 19 Oct 2026 close, ranking 1089th among the NSE companies Pivot tracks.
What is the P/E ratio of Fredun Pharmace?
Fredun Pharmace trades at a trailing P/E of 23.4. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 23.5.
What is the ROE and ROCE of Fredun Pharmace?
Return on equity was 14.7% in FY25 and return on capital employed was 31.8% in FY25 (standalone figures).
Is Fredun Pharmace a debt-free company?
No. Fredun Pharmace's debt-to-equity ratio was 1.18 in FY25, with total debt of ₹10 Cr.
What is the shareholding pattern of Fredun Pharmace?
As of 16 Jul 2026: promoters 44.57%, foreign institutions 1.06%, domestic institutions 2.94%, non-institutions 51.43%.
Who are Fredun Pharmace's competitors?
The listed Pharma & Healthcare companies closest to Fredun Pharmace by market cap are Dr Agarwals Eye Hospital, Alembic, Venus Remedies, Dishman Carbogen Amcis, Vimta Labs and Medi Assist Healthcare Services.
Is Fredun Pharmace a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Fredun Pharmace's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on FREDUN against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with F · all NSE stocks · this page as text